Ariz. Admin. Code § R9-7-723 - Training for Use of Unsealed Radioactive Material Requiring a Written Directive, Including Treatment of Hyperthyroidism, and Treatment of Thyroid Carcinoma
A.
Except as provided in
R9-7-710,
the licensee shall require an authorized user of unsealed radioactive material
for the uses authorized under Group 300 in Exhibit A, Medical Use Groups of
this Article to be a physician who:
1. Is
certified by a medical specialty board whose certification process has been
recognized by the NRC or an Agreement State, as specified in the NRC's Medical
Uses Licensee Toolkit available through https://www.nrc.gov, and who meets the
requirements in subsection (A)(2). To have its certification process
recognized, a specialty board shall require all candidates for certification
to:
a. Successfully complete residency
training in a radiation therapy or nuclear medicine training program or a
program in a related medical specialty. These residency training programs must
include 700 hours of training and experience as described in (A)(2) subsection
(A)(2)(a). Eligible training programs must be approved by the Residency Review
Committee of the Accreditation Council for Graduate Medical Education, the
Royal College of Physicians and Surgeons of Canada, or the Council on
Postdoctoral Training of the American Osteopathic Association; and
b. Pass an examination, administered by
diplomates of the specialty board, which tests knowledge and competence in
radiation safety, radionuclide handling, and quality assurance, and clinical
use of unsealed radioactive material for which a written directive is required;
or
2. Has:
a. Completed 700 hours of training and
experience, including a minimum of 200 hours of classroom and laboratory
training, in basic radionuclide handling techniques applicable to the medical
use of unsealed radioactive material requiring a written directive. The
training and experience must include:
i.
Classroom and laboratory training in the following areas:
(1) Radiation physics and
instrumentation;
(2) Radiation
protection;
(3) Mathematics
pertaining to the use and measurement of radioactivity;
(4) Chemistry of radioactive material for
medical use; and
(5) Radiation
biology; and
ii. Work
experience, under the supervision of an authorized user who meets the
requirements in this Article, NRC, or equivalent Agreement State requirements,
involving:
(1) Ordering, receiving, and
unpacking radioactive materials safely and performing the related radiation
surveys;
(2) Performing quality
control procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters;
(3) Calculating, measuring, and safely
preparing patient or human research subject dosages;
(4) Using administrative controls to prevent
a medical event involving the use of unsealed radioactive material;
(5) Using procedures to contain spilled
radioactive material safely and using proper decontamination
procedures;
(6) Administering
dosages of radioactive drugs to patients or human research subjects involving a
minimum of three cases in each of the following categories for which the
individual is requesting authorized user status:
(a) Oral administration of less than or equal
to 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131, for which a
written directive is required (Experience with at least three cases in the
Category specified in subsection (A)(2)(a)(ii)(6)(b) also satisfies this
requirement;
(b) Oral
administration of greater than 1.22 gigabecquerels (33 millicuries) of sodium
iodide I-131;
(c) Parenteral
administration of any beta emitter, or a photon-emitting radionuclide with a
photon energy less than 150 keV, for which a written directive is required;
and/or
(d) Parenteral
administration of any other radionuclide, for which a written directive is
required; and
b. Obtained written attestation, that the
individual has satisfactorily completed the requirements in subsection
(A)(2)(a) and is able to independently fulfill the radiation safety-related
duties as an authorized user for the medical uses authorized under Group 300 in
Exhibit A, Medical Use Groups of this Article for which the individual is
requesting authorized user status. The attestation must be obtained from
either:
i. A preceptor authorized user who
meets the requirements in this Section or equivalent Agreement State or NRC
requirements and has experience in administering dosages in the same dosage
category or categories as the individual requesting authorized user status;
or
ii. A residency program director
who affirms in writing that the attestation represents the consensus of the
residency program faculty where at least one faculty member is an authorized
user who meets the requirements in this Section or equivalent Agreement State
or NRC requirements, has experience in administering dosages in the same dosage
category or categories as the individual requesting authorized user status, and
concurs with the attestation provided by the residency pro-gram director. The
residency training program must be approved by the Residency Review Committee
of the Accreditation Council for Graduate Medical Education or the Royal
College of Physicians and Surgeons of Canada or the Council on Postdoctoral
Training of the American Osteopathic Association and must include training and
experience specified in subsection (A)(2)(a).
B. Except as provided in
R9-7-710,
a licensee shall require an authorized user of iodine-131 for the oral
administration of sodium iodide I-131 requiring a written directive in
quantities less than or equal to 1.22 gigabecquerels (33 millicuries) to be a
physician who has completed the training requirements in
10
CFR 35.392, January 1, 2013, incorporated by
reference, and available under
R9-7-101.
This incorporated material contains no future editions or amendments.
C. Except as provided in
R9-7-710,
a licensee shall require an authorized user of iodine-131 for the oral
administration of sodium iodide I-131 requiring a written directive in
quantities greater than 1.22 gigabecquerels (33 millicuries) to be a physician
who has completed the training requirements in
10
CFR 35.394, January 1, 2013, incorporated by
reference, and available under
R9-7-101.
This incorporated material contains no future editions or amendments.
D. Except as provided in
R9-7-710,
a licensee shall require an authorized user for the parenteral administration
of unsealed radioactive material requiring a written directive to be a
physician who has completed the training requirements in
10
CFR 35.396, January 1, 2013, incorporated by
reference, and available under
R9-7-101.
This incorporated material contains no future editions or amendments.
E. The training and experience shall have
been obtained within the seven years preceding the date of application or the
individual shall have had related continuing education and experience since the
required training and experience was completed.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.